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Edited by Gerrit van MeerAbstract The cytosolic sialidase Neu2 is known to be involved
in myoblast diﬀerentiation. Here, we observed a Neu2 transcrip-
tional induction during nerve growth factor, ﬁbroblast growth
factor 2 and epidermal growth factor treatments of PC12 cells, a
favored model to study neuronal diﬀerentiation. The expression
analysis of Neu2 deleted promoter revealed a remarkable
increase of luciferase activity in treated PC12 cells, suggesting
that in this cell line the Neu2 transcriptional levels are highly
regulated.
The enzymatic activity of cytosolic sialidase Neu2 was found
to increase transiently only during diﬀerentiation, whereas was
undetectable in untreated PC12 cells. These data suggest a
possible involvement of cytosolic sialidase Neu2 in diﬀerentiation
of PC12 cells.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Diﬀerentiation1. Introduction
Sialidases (EC 3.2.1.18) are exoglicosidases catalyzing the
removal of sialic acids from glycoproteins and glycolipids.
These enzymes cleave terminal a2! 3, a2! 6 and a2! 8 sialyl
linkages and are implicated in biological phenomena such as
diﬀerentiation, proliferation, signal transduction and cell sur-
face interactions [1]. Alterations in sialylation levels have been
observed during malignant transformation correlating with a
change of phenotype in terms of metastatic potential and in-
vasiveness [2–4]. Several mammalian sialidases have been pu-
riﬁed and cloned, and the classiﬁcation is based on their
subcellular localization [5]. They are lysosomal (Neu1), cyto-
solic (Neu2) and plasma membrane bound (Neu3). Recently, a
new sialidase named Neu4 was cloned from murine brain [6].
Membrane sialidases speciﬁcally hydrolyze gangliosides in-
ﬂuencing the pathways of transduction and cell–cell interac-
tions [7–10]. The lysosomal sialidase is a glycoprotein that is
only active as a part of a molecular multienzymatic complex
that contains b-galactosidase and cathepsin A [11,12]. Lyso-* Corresponding author. Fax: +39-30-3701157.
E-mail address: fanzani@med.unibs.it (A. Fanzani).
Abbreviations: NGF, nerve growth factor; FGF-2, ﬁbroblast growth
factor 2; EGF, epidermal growth factor; PCR, polymerase chain
reaction; 4-MUB-NANA, 4-methylumbelliferyl N-acetylneuraminic
acid; MMLV-RT, Moloney murine leukemia virus reverse transcrip-
tase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase
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sialidosis (OMIM 256550) [13] and galactosialidosis (OMIM
256540) [14], diseases that show a deﬁciency in sialidase ac-
tivity. Among the sialidases, the cytosolic form Neu2 normally
shows the lower expression level. The cytosolic enzyme is
highly expressed in skeletal muscle: in particular, the inhibition
of Neu2 translation by a speciﬁc oligodeoxyribonucleotide
antisense inhibits the myoblasts diﬀerentiation [15] and the
overexpression of the enzyme in C2C12 myoblasts induces a
spontaneous diﬀerentiation [16].
Despite its relative abundance in skeletal muscle, cytosolic
sialidase was found also in other tissues, such as liver [17],
thymus [18] and, although at low levels, brain [19].
In the present work, the expression levels of cytosolic siali-
dase Neu2 were investigated for the ﬁrst time in PC12 cells, a
favored model to study neuronal diﬀerentiation, also gener-
ating stable transfected clones overexpressing the rat Neu2
enzyme.2. Materials and methods
2.1. Cell line
PC12 cells were cultured at 37 C (in an atmosphere of 5% CO2) in
RPMI medium (Sigma–Aldrich) supplemented with 10% (v/v) horse
serum (Sigma–Aldrich), 5% (v/v) fetal bovine serum (Sigma–Aldrich),
glutamine 2 mM (Sigma–Aldrich), and 100 lg/ml penicillin/strepto-
mycin (Sigma–Aldrich). To induce diﬀerentiation, cells at 50% of
density were treated with nerve growth factor (NGF) 100 ng/ml (Al-
omon) or human ﬁbroblast growth factor 2 (FGF-2) 50 ng/ml (ex-
pressed in Chinese hamster ovary cells and puriﬁed as described [20]).
To induce proliferation, cells were treated with epidermal growth
factor (EGF) 50 ng/ml (Gibco).
2.2. Western blot
For the nuclear extracts, cells were rinsed and harvested with lysis
buﬀer (Tris 20 mM, pH 7.4, NaCl 150 mM, EDTA 1 mM, Triton 0.3%
(w/v), sodium ﬂuoride 0.1 mM (Sigma–Aldrich), and sodium ortho-
vanadate 0.1 mM (Sigma–Aldrich), added with protease inhibitor mix
(Complete Mini Protease Inhibitors, Roche Molecular Biochemicals),
vortexed and centrifuged at 12 000 g for 10 min at 4 C.
Protein concentration of the supernatant was assessed by Coomassie
assay (Pierce Reagent) according to the manufacturer’s instructions.
Aliquots (15 lg) of proteins were analyzed by Western blotting using
1:1000 dilution of monoclonal anti-phospho p42/44 MAP Kinase an-
tibody (Santa Cruz Biotechnology). Immunocomplexes were visualized
using enhanced chemiluminescence reagent (Pierce) according to the
manufacturer’s instructions.
2.3. RNA extraction and RT-PCR analysis
Total RNA was obtained as described by Chomczynski and Sacchi
[22]. The pellet of RNA was resuspended in RNAase free water, di-
gested with 1 unit of DNAase (DNA-free, Ambion) for 1 h at 37 C
according to the manufacturer’s instructions. 2 lg of total RNA was
retrotranscribed with 400 units of Moloney murine leukemia virusblished by Elsevier B.V. All rights reserved.
Fig. 1. PC12 cells diﬀerentiation and proliferation. (A) Morphology of
PC12 cells treated with NGF 100 ng/ml for two days (panel a) and with
EGF 50 ng/ml (panel b). The cells were photographed under a phase
contrast microscope. Note the neurite outgrowth in PC12 cells diﬀer-
entiated with NGF (panel a). (B) Western blot analysis of ERK 1/2
phosphorylation in PC12 cells treated with NGF or EGF. Cells were
serum starved for 12 h and then were added with NGF 100 ng/ml or
EGF 50 ng/ml. 15 lg of proteins were probed with monoclonal anti-
phospho ERK 42/44 antibodies.
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RT template was used for polymerase chain reaction (PCR) ampliﬁ-
cation (RT+). Also 2 lg of total RNA was used as template for PCR
ampliﬁcation (RT)) in order to exclude the presence of genomic DNA.
For RT-PCR analysis of endogenous rat cytosolic Neu2 sialidase ex-
pression, primers 50-CCGTCCAGGACCTCACAGAG-30 (sense) and
50-TCACTGAGCACCATGTACTG-30 (antisense) were used. Ampli-
ﬁcation was performed at 61 C of annealing up to 38 cycles. For the
screening of Neu2 transfectants, PCR analysis was performed using
the same primers utilized to clone the rat Neu2 cDNA into its ex-
pression vector in order to avoid ampliﬁcation of the endogenous
Neu2 mRNA. Ampliﬁcations were performed at 65 C of annealing up
to 30 cycles. For RT-PCR analysis of glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) expression, the primers 50-CGTGGAGTC-
TACTGGCGTCTTC-30 (sense) and 50-GGGAGTTGTCATAT-
TTCTCGTGGTT-30 (antisense) were used. Ampliﬁcation was
performed at 60 C of annealing up to 22 cycles.
2.4. Plasmids construction
The -1415/-5 fragment of the Neu2 rat promoter prior to ATG
initiation codon [21], i.e., RP1/1410, was obtained by PCR ampliﬁca-
tion of rat genomic DNA as previously described [16]. Next, the Neu2
rat promoter was cloned into the KpnI site of the luciferase reporter
expression vector pGL2-Basic (Promega), thus generating the pGL2-
Basic-Neu2 rat promoter vector.
The deletion fragments of the promoter were obtained by PCR
ampliﬁcation of the -1415/-5 fragment using in 30 the antisense primer
50-GGGGTACCCC/TGAGATCTGGGCAGAAAGAGAAGAC-30
and in 50 internal primers (50-GGGGTACCCC/CTAAATTTTAG-
TCTGCTGCATTGTC-30 for the fragment of 1280 bp, i.e., RP1/1280,
50-GGGGTACCCC/CAGCCAAGGGTGGTTACTCTGGCTT-30
for the fragment of 815 bp, i.e., RP1/815, 50-ATCGGGGTACCCC/
TGGAACAGCTTTCTAGGGCTC-30 for the fragment of 401 bp, i.e.,
RP1/401, 50-ATCGGGGTACCCC/TTCGATTCTTGGGGTAGAA-
GAC-30 for the fragment of 215 bp, i.e., RP1/215). Ampliﬁcations were
performed at 65 C of annealing up to 31 cycles.
The rat Neu2 sialidase cDNA coding sequence was ampliﬁed from a
PC12 cell cDNA library using the primers 50-CGGAATTCCG/AT-
GGAGACCTGCCCCGTCCTCCAGA-30 (sense) and 50-CGGA-
ATTCCG/TCACTGAGCACCATGTACTGTGGGA-30 (antisense)
under the following conditions: 95 C for 2 min, 59 C for 1 min, 72 C
for 3.5 min followed by 9 cycles of 94 C for 30 s, 59 C for 30 s, 72 C
for 3.5 min, followed by 34 cycles of 94 C for 30 s, 66 C for 30 s,
72 C for 3.5 min. Then, the rat Neu2 cDNA was cloned into the
EcoRI site of pCDNA vector, thus generating the pCDNA-Neu2 ex-
pression vector.
2.5. Transient transfection assays
Transfections were performed by Fugene reagent (Roche Molecular
Biochemicals). PC12 cells (1 105/60 mm dish) were transfected with a
mix of 1 lg of plasmids containing the promoter luciferase Reporter
(pGL2-Basic-Neu2 promoter) and 10 ng of the transfection control
vector pRL-TK-Renilla luciferase. The transfections with the vectors
harboring the deleted promoters were performed using identical stoi-
chiometric amounts with respect to the pGL2-Basic-Neu2 promoter, in
the same conditions. Following transfection, the medium was added
with NGF 100 ng/ml, FGF-2 50 ng/ml or EGF 50 ng/ml. Luciferase
activity was measured in the total protein lysates using the Promega
Dual luciferase assay system. Data were corrected for transfection
eﬃciency by measuring the Renilla luciferase activity according to the
manufacturer’s instructions and normalized to 100 lg of proteins.
2.6. Stable transfection
To obtain stable Neu2-overexpressing PC12 cells and the corre-
spondingmock transfectants, cells (1 105/60mmdish)were transfected
with pCDNA-Neu2 or pCDNA expression vectors (1 lg/dish), respec-
tively, in Fugene reagent (Roche Molecular Biochemicals) according to
themanufacturer’s instructions. Stable transfectantswere obtained after
25–30 days selection in G418 antibiotic (0.5 mg/ml, Promega).
2.7. Sialidase assay
Cells were washed with phosphate buﬀer solution and sonicated at
4 C in nine volumes of 0.25 M sucrose containing 1 mM EDTA and a
mix of protease inhibitors for 5 s at an intermediate setting. Themixture was centrifuged at 600 g for 10 min and the supernatant
ultracentrifuged at 105.000 g for 90 min at 4 C. The supernatant
was used to assay the cytosolic sialidase activity. The assay mixture
contained 60 nmoles of the substrate 4-methylumbelliferyl N-acetyl-
neuraminic acid (4-MUB-NANA) (Sigma–Aldrich), 200 lg of bovine
serum albumin and aliquots of enzyme fractions (150–200 lg of pro-
teins) in a ﬁnal volume of 0.2 ml of 50 mM sodium citrate buﬀer (pH
5.8). After incubation at 37 C for 4–5 h, the reaction was terminated
by addition of 0.8 ml of 0.25 M glycine buﬀer (pH 10.4), and the
amount of 4-methylumbelliferone released was determined ﬂuoro-
metrically with an excitation wavelight of 365 nm and emission of
450 nm.3. Results
PC12 cells can be induced to diﬀerentiate into a neuronal
phenotype by NGF or FGF-2 treatments (Fig. 1A, panel a)
[23,24] and to proliferate by EGF treatment (Fig. 1A, panel b)
[25]. As previously described [26], a prolonged phosphoryla-
tion of the extracellular signal-regulated protein kinases 1/2
(ERK 1/2 or p42/44 MAP kinases) is observed during diﬀer-
entiation induced by NGF, whereas a transient activation of
ERK 1/2 is observed during proliferation induced by EGF
(Fig. 1B). During diﬀerentiation or proliferation of PC12 cells,
the Neu2 expression analysis was performed. The RT-PCR
analysis showed that Neu2 is a rare transcript in untreated
PC12 cells, in fact it is undetectable also after 38 cycles of
PCR. As shown in Fig. 2, the diﬀerentiating treatments with
NGF or FGF-2 induced a transient increase in the Neu2
mRNA steady state levels; in particular, NGF treatment
showed a stronger and prolonged increase of the Neu2 tran-
script with respect to FGF-2 treatment. In addition, the pro-
liferating EGF treatment was able to transiently stimulate the
Neu2 transcription with a peak at day 2.
To conﬁrm the Neu2 transcriptional induction, a 1.4 kb
fragment of rat Neu2 promoter [21] was cloned in a reporter
Fig. 2. Neu2 mRNA expression levels in PC12 cells treated with
growth factors. PC12 cells were cultured in the presence of NGF (100
ng/ml), FGF-2 (100 ng/ml) or EGF (50 ng/ml) for the indicated periods
of time. Neu2 transcript expression was investigated by RT-PCR
analysis, as described in Section 2, using gapdh transcript as a control.
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was responsive to neurotrophic treatments, PC12 cells were
transiently transfected with the full-length Neu2 promoter and
treated with NGF, FGF-2 or EGF. In agreement with RT-
PCR analysis, the treatment with NGF and FGF-2 enhanced
the luciferase activity (Fig. 3). As a consequence, in the cells
treated up to 72 h with NGF or FGF-2, the luciferase activity
reached, respectively, a maximum of 9 and 3-fold induction
with respect to control cells. By contrast, the treatment of the
cells with EGF did not enhance the luciferase expression.
The sequence analysis of Neu2 rat promoter performed us-
ing Transfac 4.0 software [27] revealed the presence of re-
sponsive elements involved in neuronal diﬀerentiation (Fig. 4).
In particular, within the promoter region several canonical and
non-canonical E-box (–CAxxTG–) are present, sequences
known to be signals for the binding of the basic helix–loop–
helix transcription factors [28]. In addition, several binding
sites for transcriptional factors such as SP1 [29], AP1 [30] and
for glucocorticoids receptors [31] were found. Furthermore,
typical sequences of muscle regulation such as Myog [32] andFig. 3. Neu2 promoter activity in PC12 cells treated with growth fac-
tors. Cells were transiently transfected with the expression vector
harboring the luciferase reporter gene under the control of the rat
Neu2 promoter. The day after, cells were treated with NGF, FGF-2 or
EGF and, at indicated times, the luciferase activity was measured in
the cell extracts and normalized for proteins content. The results are
means of three independent experiments. Statistical analysis was per-
formed by Student’s t-test (n ¼ 3 for each group). P < 0:05,
P < 0:01.Mef-2 [33] were found, in agreement with higher levels of si-
alidase Neu2 in the skeletal muscle. Interestingly, in the region
from 672 to 776 of promoter a sequence highly similar to a
dispersed repetitive element is present. In order to better un-
derstand the transcriptional regulation of the Neu2 promoter,
four deleted fragments of Neu2 promoter were obtained and
used in transient transfections to analyze the luciferase ex-
pression (Fig. 4).
The results demonstrated that a progressive deletion of the
promoter produced a strong increase of luciferase activity in
response to NGF. In particular, two deleted constructs, i.e.,
RP1/1280 and RP1/815, showed a 1.2 and 2.7-fold of lu-
ciferase induction with respect to the entire promoter. The
transient transfection with the fragment RP1/401 produced a
11.4-fold induction of luciferase activity, whereas the smaller
fragment generated, i.e., RP1/215, revealed a 8.5-fold in-
duction of luciferase activity.
On the basis of Neu2 transcriptional induction, enzymatic
assays were performed. The Neu2 sialidase activity was de-
tected in diﬀerentiating PC12 cells, on the contrary no Neu2
activity was found after EGF treatment (data not shown). In
particular, the Neu2 activity was detected after NGF treatment
at days 1–2 (Fig. 5A), whereas untreated PC12 cells did not
reveal the sialidase activity in the cytosolic fraction. As ex-
pected, in diﬀerentiating PC12 cells the Neu2 activity was
found to be low, but strictly correlated with the transcript
expression level obtained (Fig. 5A). In agreement, PC12 cells
stably transfected with an expression vector harboring the rat
cDNA Neu2 sialidase showed high expression of Neu2 tran-
script and enzymatic activity (Fig. 5B). As a consequence, the
enzymatic assays performed at pH of 5.8 revealed that Neu2
transfected sialidase activity was up to 25-times higher than the
NGF induced endogenous activity (Fig. 5B).4. Discussion
The cytosolic sialidase Neu2 is an enzyme particularly ex-
pressed in the skeletal muscle [15]. Recently, we demonstrated
that its overexpression induces a marked decrement of prolif-
eration and spontaneous diﬀerentiation of myoblast C2C12
cells [16]. Although the sialidase Neu2 is expressed in other
tissues such as liver [17], thymus [18] and brain [19], its enzy-
matic activity is often hardly detectable, thus making its study
diﬃcult.
In this work, the expression of cytosolic sialidase Neu2 was
investigated in PC12 cells, a favored model for the neuronal
diﬀerentiation. The RT-PCR analysis showed that cytosolic
sialidase is a rare transcript in PC12 cells, in fact the Neu2
mRNA was undetectable in untreated cells even after 38 cycles
of PCR. This was conﬁrmed on the basis of Northern blot
experiments: no Neu2 transcript was detectable also using 5 lg
of polyAþ RNA of PC12 cells (data not shown). Under dif-
ferentiating and proliferating conditions the Neu2 transcript
increased, suggesting a potential role of cytosolic sialidase in
these processes. Using a fragment of 1.4 kb of rat Neu2 pro-
moter in transient transfections of PC12 cells, the transcrip-
tional up-regulation was conﬁrmed only under diﬀerentiating
conditions. This suggests that the regions able to recognize
EGF-dependent nuclear factors could be present in the 50
upstream of this fragment promoter. The sequence analysis of
Neu2 promoter showed the presence of some typical elements
Fig. 4. Sequence analysis of Neu2 promoter and reporter activity of its deleted fragments. The sequence analysis performed using Transfac Promoter
software revealed the presence of several E-box (–CAxxTG–), SP1 and AP1 sites. In addition, several binding sites for glucocorticoids receptor (GR)
were found. From the position 672 to 776 of promoter, a dispersed repetitive element is present. The reporter vector harboring the entire Neu2
promoter (i.e., RP1/1410) and the diﬀerent deleted fragments (i.e., RP1/1280, RP1/815, RP1/401 and RP1/215) were transiently transfected in PC12
cells. After NGF treatment, the relative luciferase activity of deleted promoters was calculated as fold-induction number with respect to the activity of
entire promoter. The results are means of three independent experiments. Statistical analysis was performed by Student’s t-test (n ¼ 3 for each
group). P < 0:05, P < 0:01.
Fig. 5. Enzymatic assays of cytosolic sialidase Neu2. (A) Neu2 en-
dogenous sialidase activity was tested in PC12 cells treated with NGF
100 ng/ml until day four and, in parallel, its transcriptional level was
obtained by RT-PCR analysis. (B) Neu2 sialidase activity of PC12 cells
stably transfected with the pCDNA-Neu2 vector. After selection,
transfectants (i.e., N54, N42 and N58) were compared to parental and
mock-transfected cells for rat Neu2 expression by RT-PCR analysis
and tested for cytosolic Neu2 sialidase activity. In the upper panel, we
report the eﬀect of pH on cytosolic Neu2 activity using the N58 clone.
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binding sites for the nuclear factors SP1 [29] and AP1 [30] and
several E-box sequences [28]. Since cooperation between dif-
ferent E boxes present on the same promoter is a common
ﬁnding in transcriptional regulation of tissue-speciﬁc genes
[34,35], it is possible that these elements play an important role
in Neu2 transcriptional regulation. Interestingly, the remark-
able increase of reporter activity obtained by the progressivedeletion of Neu2 promoter revealed that within the promoter
sequence could exist some regulatory regions that maintain a
very low Neu2 expression. In particular, the deletion of the
fragment containing a rat dispersed repetitive element caused
the major increase of luciferase activity. However, it has been
shown that the presence of repetitive sequences in the 50-
untranslated region (50-UTR) of some genes can inﬂuence
expression. For example, repetitive elements in the 50-UTR of
a human zinc-ﬁnger gene modulate transcription and transla-
tion eﬃciency [36].
The Neu2 enzymatic activity was detectable in PC12 cells at
day 1–2 of NGF diﬀerentiation, suggesting a potential role of
this sialidase in the early steps of neuronal diﬀerentiation. The
low activity seems to be correlated to its transcriptional levels;
in agreement the Neu2 activity in the cytosol of transfectants
was found up to 25-times higher than the endogenous activity.
The treatment with EGF did not reveal Neu2 activity, but it is
possible that a very transient sialidase activity could be present
also during EGF induced proliferation.
The role of cytosolic sialidase Neu2 is still unclear, but its
reported ability to hydrolyze gangliosides and glycoproteins
[37] could inﬂuence the sialylation pattern of the glycoconju-
gates in the cells.
The association of glycosphingolipids to the cytoskeleton in
diﬀerent cell types has been demonstrated [38,39]. As a con-
sequence, the modulation of endogenous gangliosides may
represent an early event in cell diﬀerentiation preceding neurite
outgrowth. In keeping with this hypothesis, Neu2 overex-
pression has been shown to modulate melanoma cell inva-
siveness and migration, two processes strictly linked to
cytoskeleton functions [40]. Furthermore, the availability of
free sialic acids can inﬂuence the expression pattern of sialo-
glycoproteins that play an important role during neuronal
processes, in particular during cellular adhesion [41,42]. An
increase of free sialic acid at cytoplasmatic and nuclear level, in
fact, could represent a potent signal for enhancing the activity
of sialyl- and polysialyltransferases. Further studies are in
progress in our laboratories in order to better understand the
182 A. Fanzani et al. / FEBS Letters 566 (2004) 178–182role of the cytosolic sialidase Neu2 in PC12 cells, also through
the characterization of Neu2 transfectants.
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